Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 11Active not recruiting 6Terminated 5Withdrawn 3Completed 2Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

pembrolizumab 439Carboplatin 323Nivolumab 291Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 254Paclitaxel 249Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 169atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Radiosurgery 114Oxaliplatin 114Pemetrexed 113Etoposide 111Fluorouracil 110venetoclax 108fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × loncastuximab tesirine × Clear all
NCT05190705 2026-05-20

Loncastuximab Tesirine in WM

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
21 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT04384484 2026-04-28

LOTIS 5

ADC Therapeutics S.A.

Phase 3 Active not recruiting
440 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05658562 2026-02-13

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Tanabe Pharma Corporation

Phase 1/2 Active not recruiting
46 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05053659 2026-02-12

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT05270057 2025-10-09

LONCA

Medical College of Wisconsin

Phase 1 Active not recruiting
11 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT05971251 2025-10-01

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

University of Alabama at Birmingham

Phase 1 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡